Thymosin Beta-4

The Endogenous Protein

Thymosin beta-4 is a 43-amino-acid, 4.9 kDa intracellular protein encoded by the TMSB4X gene on the human X chromosome. It is one of the most abundant proteins in mammalian cells — present at concentrations near 0.5 mM in platelets and polymorphonuclear leukocytes — and its principal biochemical role is binding monomeric G-actin, thereby regulating the pool of actin available for filament assembly. It was first isolated from bovine thymus tissue in the 1980s by Allan Goldstein's group at The George Washington University, which also characterized the broader thymosin family.

Unlike many bioactive peptides, thymosin beta-4 is not a signaling peptide secreted into circulation for receptor binding. It acts largely inside the cell as an actin sequestering protein, and its extracellular effects — which underpin its clinical development — appear to result from its release during cell damage or active secretion from platelets at wound sites.

Mechanism in Tissue Repair

The tissue-repair effects of thymosin beta-4 appear to operate through several converging pathways:

• Actin cytoskeleton regulation. By buffering G-actin, the protein allows rapid cytoskeletal remodeling required for cell migration into wound beds.
• Angiogenesis. Thymosin beta-4 induces VEGF expression and endothelial cell migration, promoting vascularization of injured tissue.
• Anti-apoptotic and anti-inflammatory signaling. It downregulates several pro-inflammatory cytokines and inhibits apoptosis in cardiomyocytes and corneal epithelial cells.
• Progenitor cell activation. Work from Paul Riley's group at Oxford reported that thymosin beta-4 can activate quiescent epicardial progenitor cells in the adult mouse heart, a finding that drove substantial interest in cardiac regeneration.

Clinical Trial History

Thymosin beta-4 was developed under the sponsorship of RegeneRx Biopharmaceuticals, which ran the bulk of the human trials in the 2000s and 2010s. Three indications received the most attention:

• Dry eye disease. A topical ophthalmic formulation (RGN-259) progressed through multiple Phase 3 trials for dry eye and neurotrophic keratopathy, with mixed outcomes on primary endpoints across studies.
• Chronic dermal wounds. A topical gel (RGN-137) was evaluated in Phase 2 trials for epidermolysis bullosa and pressure ulcers.
• Acute myocardial infarction. Preclinical cardiac-repair data generated substantial interest, but human cardiac trials did not advance to confirmatory studies.

As of early 2026, no thymosin beta-4 product has received FDA approval, though the Korean licensee ReGenTree has continued development in ophthalmic indications internationally.

Distinction from TB-500

The research-chemical compound sold as TB-500 is typically not full-length thymosin beta-4 but a truncated synthetic fragment corresponding to the actin-binding region. This is a meaningful distinction: the full 43-residue protein has been extensively characterized in regulated clinical trials, while the truncated TB-500 fragment has essentially no human trial record. Marketing materials that conflate the two borrow credibility from the RegeneRx clinical program that does not transfer cleanly.

Safety and Regulatory Status

In regulated trials of full-length thymosin beta-4 (topical and intravenous), the safety profile has been generally favorable, with adverse events limited mostly to local reactions for topical use and mild infusion reactions for systemic dosing. The theoretical concern that a pro-angiogenic, anti-apoptotic protein could promote occult tumor growth has been flagged in every development program; long-term oncologic surveillance data remain limited.

Thymosin beta-4 is listed by the World Anti-Doping Agency under class S2 and is prohibited at all times in competitive sport. It is also included in the FDA's Category 2 bulk drug substance restriction, alongside its truncated TB-500 analogue.

Bottom Line

Thymosin beta-4 is one of the better-characterized tissue-repair proteins from a mechanistic standpoint, with a real (if unfinished) clinical development history. The gap between that history and the research-chemical market for TB-500 is where most of the confusion lives. For broader recovery-peptide context see our recovery peptide overview.